Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Avecho Biotechnology Limited ( (AU:AVE) ) just unveiled an update.
Avecho Biotechnology will present at the NWR Virtual Healthcare Conference on 25 March 2026, with CEO Dr Paul Gavin outlining the company’s progress and making the session accessible to investors via live stream and subsequent online replay. The appearance comes as Avecho advances a large, multi-centre Phase III trial of its CBD TPM soft-gel capsule for insomnia, positioning the company to capitalise on regulatory settings that could enable over-the-counter CBD sales in Australia and to compete in a sleep economy projected to approach US$1 trillion globally by 2032.
The most recent analyst rating on (AU:AVE) stock is a Hold with a A$0.01 price target. To see the full list of analyst forecasts on Avecho Biotechnology Limited stock, see the AU:AVE Stock Forecast page.
More about Avecho Biotechnology Limited
Avecho Biotechnology Limited is an Australian biopharmaceutical company developing human and animal health products based on its proprietary Tocopheryl Phosphate Mixture (TPM) drug delivery technology, derived from vitamin E to enhance solubility and absorption of drugs and nutrients. Its lead asset is a CBD TPM soft-gel capsule in Phase III development for treating insomnia, targeting the expanding global sleep-disorder and sleep-aids market.
Average Trading Volume: 6,150,485
Technical Sentiment Signal: Sell
Current Market Cap: A$33.06M
Find detailed analytics on AVE stock on TipRanks’ Stock Analysis page.